FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296942186> ?p ?o ?g. }

• W2296942186 endingPage "LBA502" @default.
• W2296942186 startingPage "LBA502" @default.
• W2296942186 abstract "LBA502 Background: The growth of hormone receptor (HR) positive breast cancer (BC) is dependent on the cyclin dependent kinases CDK4/6, that promote G1-S phase cell cycle progression. Resistance to endocrine treatment remains a major clinical problem for patients with hormone receptor positive breast cancer. The PALOMA3 study assessed the efficacy of palbociclib and fulvestrant in endocrine-resistant advanced breast cancer. Methods: In this double-blind phase 3 study women with HR positive/HER2 negative advanced metastatic BC whose cancer had relapsed or progressed on prior endocrine therapy, were randomized 2:1 to palbociclib (Palbo, 125 mg/d orally for 3 wk followed by 1 wk off) and fulvestrant (F, 500 mg per standard of care) or placebo (PLB) and F. Pre- and peri-menopausal women also received goserelin. One previous line of chemotherapy for metastatic disease was permitted. The primary endpoint was investigator assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), response assessment, patient-reported outcomes, and safety and tolerability. A pre-planned interim analysis was performed after 195 PFS events by an independent data monitoring committee. Results: 521 pts were randomized, 347 to receive Palbo+F and 174 to PLB+F. Baseline characteristics were well balanced. The median age was 57 and 56 years, 79% were post-menopausal, 60% had visceral disease, and 79% were sensitive to prior endocrine therapy. Prior therapy included chemotherapy for advanced disease in 33% of pts. At the time of the interim analysis the study met the primary endpoint, median PFS was 9.2 months for Palbo+F and 3.8 months for PLB+F (HR 0.422, 95% CI 0.318 to 0.560, P<0.000001). Consistent benefit from Palbo was seen in pre- and post-menopausal women. The most common adverse effects Palbo+F versus PLB+F were neutropenia (78.8% vs. 3.5%), leucopenia (45.5% vs. 4.1%), and fatigue (38.0% vs. 26.7%). Febrile neutropenia was reported in 0.6% pts on Palbo+F and 0.6% pts on PLB+F. The discontinuation rate due to adverse events was 2.0% on Palbo and 1.7% on PLB. Conclusions: Palbociclib combined with fulvestrant improved progression free survival in hormone receptor positive advanced breast cancer that had progressed on prior endocrine therapy, and can be considered as a treatment option for these patients. Clinical trial information: NCT01942135." @default.
• W2296942186 created "2016-06-24" @default.
• W2296942186 creator A5001814176 @default.
• W2296942186 creator A5008549101 @default.
• W2296942186 creator A5010278367 @default.
• W2296942186 creator A5027231412 @default.
• W2296942186 creator A5032987754 @default.
• W2296942186 creator A5033939248 @default.
• W2296942186 creator A5046221783 @default.
• W2296942186 creator A5047768231 @default.
• W2296942186 creator A5048598383 @default.
• W2296942186 creator A5051676656 @default.
• W2296942186 creator A5052936351 @default.
• W2296942186 creator A5075711437 @default.
• W2296942186 creator A5075821163 @default.
• W2296942186 creator A5087559224 @default.
• W2296942186 date "2015-06-20" @default.
• W2296942186 modified "2023-10-05" @default.
• W2296942186 title "PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy." @default.
• W2296942186 doi "https://doi.org/10.1200/jco.2015.33.18_suppl.lba502" @default.
• W2296942186 hasPublicationYear "2015" @default.
• W2296942186 type Work @default.
• W2296942186 sameAs 2296942186 @default.
• W2296942186 citedByCount "13" @default.
• W2296942186 countsByYear W22969421862015 @default.
• W2296942186 countsByYear W22969421862016 @default.
• W2296942186 countsByYear W22969421862017 @default.
• W2296942186 countsByYear W22969421862018 @default.
• W2296942186 countsByYear W22969421862019 @default.
• W2296942186 countsByYear W22969421862020 @default.
• W2296942186 crossrefType "journal-article" @default.
• W2296942186 hasAuthorship W2296942186A5001814176 @default.
• W2296942186 hasAuthorship W2296942186A5008549101 @default.
• W2296942186 hasAuthorship W2296942186A5010278367 @default.
• W2296942186 hasAuthorship W2296942186A5027231412 @default.
• W2296942186 hasAuthorship W2296942186A5032987754 @default.
• W2296942186 hasAuthorship W2296942186A5033939248 @default.
• W2296942186 hasAuthorship W2296942186A5046221783 @default.
• W2296942186 hasAuthorship W2296942186A5047768231 @default.
• W2296942186 hasAuthorship W2296942186A5048598383 @default.
• W2296942186 hasAuthorship W2296942186A5051676656 @default.
• W2296942186 hasAuthorship W2296942186A5052936351 @default.
• W2296942186 hasAuthorship W2296942186A5075711437 @default.
• W2296942186 hasAuthorship W2296942186A5075821163 @default.
• W2296942186 hasAuthorship W2296942186A5087559224 @default.
• W2296942186 hasConcept C121608353 @default.
• W2296942186 hasConcept C126322002 @default.
• W2296942186 hasConcept C143998085 @default.
• W2296942186 hasConcept C197934379 @default.
• W2296942186 hasConcept C203092338 @default.
• W2296942186 hasConcept C2775930923 @default.
• W2296942186 hasConcept C2777176818 @default.
• W2296942186 hasConcept C2778043895 @default.
• W2296942186 hasConcept C2778375690 @default.
• W2296942186 hasConcept C2779744173 @default.
• W2296942186 hasConcept C2780482068 @default.
• W2296942186 hasConcept C29456083 @default.
• W2296942186 hasConcept C530470458 @default.
• W2296942186 hasConcept C535046627 @default.
• W2296942186 hasConcept C61943457 @default.
• W2296942186 hasConcept C71924100 @default.
• W2296942186 hasConceptScore W2296942186C121608353 @default.
• W2296942186 hasConceptScore W2296942186C126322002 @default.
• W2296942186 hasConceptScore W2296942186C143998085 @default.
• W2296942186 hasConceptScore W2296942186C197934379 @default.
• W2296942186 hasConceptScore W2296942186C203092338 @default.
• W2296942186 hasConceptScore W2296942186C2775930923 @default.
• W2296942186 hasConceptScore W2296942186C2777176818 @default.
• W2296942186 hasConceptScore W2296942186C2778043895 @default.
• W2296942186 hasConceptScore W2296942186C2778375690 @default.
• W2296942186 hasConceptScore W2296942186C2779744173 @default.
• W2296942186 hasConceptScore W2296942186C2780482068 @default.
• W2296942186 hasConceptScore W2296942186C29456083 @default.
• W2296942186 hasConceptScore W2296942186C530470458 @default.
• W2296942186 hasConceptScore W2296942186C535046627 @default.
• W2296942186 hasConceptScore W2296942186C61943457 @default.
• W2296942186 hasConceptScore W2296942186C71924100 @default.
• W2296942186 hasIssue "18_suppl" @default.
• W2296942186 hasLocation W22969421861 @default.
• W2296942186 hasOpenAccess W2296942186 @default.
• W2296942186 hasPrimaryLocation W22969421861 @default.
• W2296942186 hasRelatedWork W2296942186 @default.
• W2296942186 hasRelatedWork W2751810360 @default.
• W2296942186 hasRelatedWork W2962497808 @default.
• W2296942186 hasRelatedWork W3031130887 @default.
• W2296942186 hasRelatedWork W3093743109 @default.
• W2296942186 hasRelatedWork W3203690439 @default.
• W2296942186 hasRelatedWork W4220872882 @default.
• W2296942186 hasRelatedWork W4282924254 @default.
• W2296942186 hasRelatedWork W4295817034 @default.
• W2296942186 hasRelatedWork W4323050407 @default.
• W2296942186 hasVolume "33" @default.
• W2296942186 isParatext "false" @default.
• W2296942186 isRetracted "false" @default.
• W2296942186 magId "2296942186" @default.
• W2296942186 workType "article" @default.